Orencia (Abatacept) (Rheumatoid Arthritis) Market Size, Share, Trends and Forecast 2016

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

BMS' Orencia (abatacept) is a soluble biologic, and structurally, is a fully-humanized fusion protein of the extracellular domain of the human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with the Fc domain of human IgG1. The drug functions by preventing T-cell activation. The co-stimulatory molecules CD80 and CD86 are able to bind to CTLA-4, which typically blocks T-cell activation, or to CD28, which activates T cells. Because CTLA-4 has a higher affinity for CD80 and CD86, Orencia is able to block the activation of T cells by competing with CD28 for binding to CD80/CD86.

Browse Detail Report With TOC @ http://www.hexareports.com/report/orencia-abatacept-rheumatoid-arthritis-forecast-and-market-analysis-to-2023/details

Scope

Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Orencia (Abatacept) including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Orencia (Abatacept) for...